Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 54
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Biol Chem ; 300(5): 107294, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38636665

RESUMEN

Exenatide, a promising cardioprotective agent, protects against cardiac structural remodeling and diastolic dysfunction. Combined blockade of sodium and potassium channels is valuable for managing atrial fibrillation (AF). Here, we explored whether exenatide displayed anti-AF effects by inhibiting human Kv1.5 and Nav1.5 channels. We used the whole-cell patch-clamp technique to investigate the effects of exenatide on hKv1.5 and hNav1.5 channels expressed in human embryonic kidney 293 cells and studied the effects of exenatide on action potential (AP) and other cardiac ionic currents in rat atrial myocytes. Additionally, an electrical mapping system was used to explore the effects of exenatide on electrical properties and AF activity in isolated rat hearts. Finally, a rat AF model, established using acetylcholine and calcium chloride, was employed to evaluate the anti-AF potential of exenatide in rats. Exenatide reversibly suppressed IKv1.5 with IC50 of 3.08 µM, preferentially blocked the hKv1.5 channel in its closed state, and positively shifted the voltage-dependent activation curve. Exenatide also reversibly inhibited INav1.5 with IC50 of 3.30 µM, negatively shifted the voltage-dependent inactivation curve, and slowed its recovery from inactivation with significant use-dependency at 5 and 10 Hz. Furthermore, exenatide prolonged AP duration and suppressed the sustained K+ current (Iss) and transient outward K+ current (Ito), but without inhibition of L-type Ca2+ current (ICa,L) in rat atrial myocytes. Exenatide prevented AF incidence and duration in rat hearts and rats. These findings demonstrate that exenatide inhibits IKv1.5 and INav1.5in vitro and reduces AF susceptibility in isolated rat hearts and rats.


Asunto(s)
Potenciales de Acción , Fibrilación Atrial , Exenatida , Canal de Potasio Kv1.5 , Miocitos Cardíacos , Canal de Sodio Activado por Voltaje NAV1.5 , Bloqueadores del Canal de Sodio Activado por Voltaje , Animales , Humanos , Masculino , Ratas , Potenciales de Acción/efectos de los fármacos , Fibrilación Atrial/tratamiento farmacológico , Fibrilación Atrial/metabolismo , Exenatida/farmacología , Exenatida/uso terapéutico , Células HEK293 , Canal de Potasio Kv1.5/antagonistas & inhibidores , Miocitos Cardíacos/efectos de los fármacos , Miocitos Cardíacos/metabolismo , Canal de Sodio Activado por Voltaje NAV1.5/metabolismo , Canal de Sodio Activado por Voltaje NAV1.5/genética , Ratas Sprague-Dawley , Bloqueadores del Canal de Sodio Activado por Voltaje/farmacología , Bloqueadores del Canal de Sodio Activado por Voltaje/uso terapéutico
2.
J Integr Neurosci ; 19(4): 663-671, 2020 Dec 30.
Artículo en Inglés | MEDLINE | ID: mdl-33378840

RESUMEN

The effects of Danggui Sini decoction on peripheral neuropathy in oxaliplatin-induced peripheral is established. The results indicated that Danggui Sini decoction treatment significantly reduced the current amplitude of dorsal root ganglia cells undergoing agonists stimuli compared to the model-dorsal root ganglia group (P < 0.05). Danggui Sini decoction treatment significantly inhibited the inflammatory response of dorsal root ganglia cells compared to the model-dorsal root ganglia group (P < 0.05). Danggui Sini decoction treatment significantly enhanced the amounts of Nissl bodies in dorsal root ganglia cells compared to the Model-dorsal root ganglia group (P < 0.05). Danggui Sini decoction treatment improved ultra-microstructures of dorsal root ganglia cells. In conclusion, Danggui Sini decoction protected against neurotoxicity of oxaliplatin-induced peripheral neuropathy in rats by suppressing inflammatory lesions, improving ultra-microstructures, and enhancing amounts of Nissl bodies.


Asunto(s)
Antineoplásicos/toxicidad , Medicamentos Herbarios Chinos/farmacología , Ganglios Espinales/efectos de los fármacos , Síndromes de Neurotoxicidad/prevención & control , Oxaliplatino/toxicidad , Enfermedades del Sistema Nervioso Periférico/inducido químicamente , Enfermedades del Sistema Nervioso Periférico/prevención & control , Animales , Fenómenos Electrofisiológicos/efectos de los fármacos , Masculino , Técnicas de Placa-Clamp , Ratas , Ratas Wistar
3.
Mol Cell Biochem ; 455(1-2): 119-125, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-30535530

RESUMEN

Hepatocellular carcinoma (HCC) is one of leading causes of cancer-related death, and its increasing incidence worldwide is a cause for concern. The recombinant analgesic-antitumor peptide (rAGAP), a protein consisting of small ubiquitin-related modifier linked with a hexa-histidine tag, exhibited the antitumor activity in HepG2 tumors in our previous study. However, the underlying molecular mechanism of its antitumor activity was still elusive. In this work, we found that treatment with rAGAP reduced phosphorylation of AKT at non-toxic doses in HepG2 cells in vitro. More importantly, treatment of HepG2 cells with rAGAP downregulated protein expression of HIF-1α, suppressed activities of HIF, reduced secretion of VEGF and IL-8, and suppressed HepG2-induced tube formation by HUVEC, which was reversed by co-incubation with SC-79 (an AKT activator). Furthermore, in tumors of athymic mice with HepG2, treatment with rAGAP reduced phosphorylation of AKT, downregulated protein expression of HIF-1α and VEGF, and microvessel density marked by positive CD31 staining. Collectively, rAGAP inhibited angiogenesis by suppressing AKT activation, which partly explained its antitumor activity in HCC.


Asunto(s)
Analgésicos/farmacología , Antineoplásicos/farmacología , Carcinoma Hepatocelular , Neoplasias Hepáticas , Neovascularización Patológica , Péptidos/farmacocinética , Proteínas Proto-Oncogénicas c-akt/metabolismo , Acetatos/farmacología , Animales , Benzopiranos/farmacología , Carcinoma Hepatocelular/irrigación sanguínea , Carcinoma Hepatocelular/tratamiento farmacológico , Carcinoma Hepatocelular/enzimología , Carcinoma Hepatocelular/patología , Activación Enzimática/efectos de los fármacos , Células Hep G2 , Células Endoteliales de la Vena Umbilical Humana/enzimología , Células Endoteliales de la Vena Umbilical Humana/patología , Humanos , Neoplasias Hepáticas/irrigación sanguínea , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/enzimología , Neoplasias Hepáticas/patología , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Neovascularización Patológica/tratamiento farmacológico , Neovascularización Patológica/enzimología , Neovascularización Patológica/patología
4.
World J Surg Oncol ; 17(1): 175, 2019 Oct 31.
Artículo en Inglés | MEDLINE | ID: mdl-31672162

RESUMEN

BACKGROUND AND OBJECTIVES: Lymph node metastasis is a key factor in predicting and determining the prognosis of patients with colorectal cancer (CRC). Sodium channels are highly expressed in a variety of tumors and are closely related to tumor development, metastasis, and invasion. We investigated the relationship between the expressions of different subtypes of Nav channels and lymph node metastasis of CRC. METHODS: Real-time PCR (RT-qPCR) was carried out to measure the expressions of different sodium channel subtypes, chemokine receptors (CCR2, CCR4, CCR7), and lymphocyte infiltration-related biomarkers (CD3e, CD8a, IL-2RA) in CRC tissues from 97 patients. The expressions of Nav1.5 and Nav1.6 in surgically isolated lymph nodes were detected by immunohistochemistry. Correlation analysis between expressions of different genes and lymph node metastasis was performed by two-tailed t test. RESULTS: Nav1.1 and Nav1.6 were highly expressed in CRC tissues and positively correlated with CRC lymph node metastasis. Nav1.6 was also highly expressed in metastatic lymph nodes. Further analysis showed that the high expression of Nav1.6 was closely related to the one of CCR2\CCR4 in tumor lymph node metastasis. CONCLUSIONS: These results suggested that Nav1.6 might be a novel marker for CRC lymph node metastasis.


Asunto(s)
Neoplasias Colorrectales/patología , Canal de Sodio Activado por Voltaje NAV1.6/análisis , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias Colorrectales/metabolismo , Femenino , Humanos , Metástasis Linfática , Linfocitos Infiltrantes de Tumor/patología , Masculino , Persona de Mediana Edad , Receptores CCR2/análisis , Receptores CCR4/análisis
5.
Mol Pain ; 14: 1744806918761238, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29424271

RESUMEN

Background Several studies have shown that scorpion venom peptide BmK AGAP has an analgesic activity. Our previous study also demonstrated that intraplantar injection of BmK AGAP ameliorates formalin-induced spontaneous nociceptive behavior. However, the effect of intrathecal injection of BmK AGAP on nociceptive processing is poorly understood. Methods We investigated the effects of intrathecal injection of BmK AGAP on spinal nociceptive processing induced by chronic constrictive injury or formalin. Thermal hyperalgesia and mechanical allodynia were measured using radiant heat and the von Frey filaments test. Formalin-induced spontaneous nociceptive behavior was also investigated. C-Fos expression was assessed by immunohistochemistry. Phosphorylated mitogen-activated protein kinase (p-MAPK) expression was monitored by Western blot assay. Results Intrathecal injection of BmK AGAP reduced chronic constrictive injury-induced neuropathic pain behavior and pain from formalin-induced inflammation, accompanied by decreased expression of spinal p-MAPKs and c-Fos protein. The results of combining low doses of different MAPK inhibitor (U0126, SP600125, or SB203580; 0.1 µg for each inhibitor) with a low dose of BmK AGAP (0.2 µg) suggested that BmK AGAP could potentiate the effects of MAPK inhibitors on inflammation-associated pain. Conclusion Our results demonstrate that intrathecal injection of BmK AGAP produces a sensory-specific analgesic effect via a p-MAPK-dependent mechanism.


Asunto(s)
Analgésicos/uso terapéutico , Proteínas Quinasas Activadas por Mitógenos/antagonistas & inhibidores , Venenos de Escorpión/uso terapéutico , Sensación , Médula Espinal/enzimología , Analgésicos/farmacología , Animales , Constricción , Modelos Animales de Enfermedad , Regulación hacia Abajo/efectos de los fármacos , Formaldehído , Hiperalgesia/complicaciones , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/patología , Inflamación/complicaciones , Inflamación/tratamiento farmacológico , Inflamación/patología , Inyecciones Espinales , Masculino , Ratones , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Neuralgia/complicaciones , Neuralgia/tratamiento farmacológico , Neuralgia/patología , Fosforilación/efectos de los fármacos , Inhibidores de Proteínas Quinasas/farmacología , Inhibidores de Proteínas Quinasas/uso terapéutico , Proteínas Proto-Oncogénicas c-fos/metabolismo , Venenos de Escorpión/administración & dosificación , Venenos de Escorpión/farmacología , Sensación/efectos de los fármacos , Médula Espinal/efectos de los fármacos , Médula Espinal/patología
6.
Nat Mater ; 14(10): 1058-64, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26280226

RESUMEN

The ability to count biomolecules such as cancer-biomarker miRNAs with the naked eye is seemingly impossible in molecular diagnostics. Here, we show an ultrasensitive naked-eye-counting strategy for quantifying miRNAs by employing T7 phage-a bacteria-specific virus nanoparticle-as a surrogate. The phage is genetically engineered to become fluorescent and capable of binding a miRNA-capturing gold nanoparticle (GNP) in a one-to-one manner. Target miRNAs crosslink the resultant phage-GNP couple and miRNA-capturing magnetic microparticles, forming a sandwich complex containing equimolar phage and miRNA. The phage is then released from the complex and developed into one macroscopic fluorescent plaque in a Petri dish by plating it in a host bacterial medium. Counting the plaques by the naked eye enables the quantification of miRNAs with detection limits of ∼3 and ∼5 aM for single-target and two-target miRNAs, respectively. This approach offers ultrasensitive and convenient quantification of disease biomarkers by the naked eye.


Asunto(s)
Bacteriófagos/fisiología , MicroARNs/metabolismo , Bacterias/metabolismo , Bacteriófago T7/química , Biomarcadores/metabolismo , Biomarcadores de Tumor/metabolismo , ADN/química , Colorantes Fluorescentes/química , Genoma Bacteriano , Oro/química , Humanos , Nanopartículas del Metal/química , Microscopía Electrónica de Transmisión , Nanotecnología , Neoplasias , Oligonucleótidos/química , Reacción en Cadena de la Polimerasa , Reproducibilidad de los Resultados
7.
Yao Xue Xue Bao ; 51(2): 294-301, 2016 02.
Artículo en Zh | MEDLINE | ID: mdl-29856584

RESUMEN

Myeloid-derived suppressor cells(MDSC) play critical roles in immune escape of tumor. We hypothesized that elimination of tumor-induced MDSCs might help to block tumor growth. Therefore, we constructed a cholera toxin B based peptide vaccine that targets a MDSC surface marker S100A8. Immunized BALB/c mice with CTB-S100A8 plus aluminum hydroxide induced high titers of anti-S100A8 antibodies and reduced tumor burden significantly in 4T1 mice model. We also found the vaccination led to significant reduction of tumor-induced monocytic MDSC(M-MDSC), with no effect on innate MDSCs, dendritic cell(DC) and macrophage(Mφ), demonstrating that targeting tumor-induced MDSC may be a promising approach in cancer immunotherapy.


Asunto(s)
Calgranulina A/antagonistas & inhibidores , Vacunas contra el Cáncer , Células Mieloides/efectos de los fármacos , Neoplasias/terapia , Vacunas de Subunidad , Animales , Línea Celular Tumoral , Macrófagos , Ratones , Ratones Endogámicos BALB C
8.
Biotechnol Lett ; 37(12): 2461-6, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26303431

RESUMEN

OBJECTIVES: To identify an efficient in vitro refolding method to generate highly active His6-tagged scorpion toxin antitumor-analgesic peptide (AGAP) isolated from Escherichia coli inclusion bodies. RESULTS: N- and C-Terminal His6-tagged recombinant (r) AGAP (NHis6-rAGAP and CHis6-rAGAP, respectively) were expressed in E. coli; the purification and refolding conditions were optimized. CHis6-rAGAP, but not NHis6-rAGAP, exhibited significant in vitro antihepatoma activity that was much greater than that of rAGAP produced using SUMO fusion technology (IC50, 0.4 ± 0.08 vs. 1.8 ± 0.3 µM). CHis6-rAGAP also showed significant inhibition of tumor growth in a mouse xenograft model of human hepatoma and inhibition of neuronal excitability, demonstrated by blockage of voltage-sensitive tetrodotoxin-resistant (TTX-R) sodium currents in acute isolated dorsal root ganglion neurons. CONCLUSIONS: This refolding protocol optimized for C-terminal His6-tagged scorpion rAGAP is potentially applicable to similar long-chain and cysteine-rich toxins.


Asunto(s)
Histidina/metabolismo , Pliegue de Proteína , Proteínas Recombinantes de Fusión/metabolismo , Venenos de Escorpión/metabolismo , Animales , Carcinoma Hepatocelular/tratamiento farmacológico , Modelos Animales de Enfermedad , Escherichia coli/genética , Expresión Génica , Xenoinjertos , Histidina/genética , Histidina/aislamiento & purificación , Histidina/uso terapéutico , Humanos , Ratones , Neuronas/efectos de los fármacos , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/aislamiento & purificación , Proteínas Recombinantes de Fusión/uso terapéutico , Venenos de Escorpión/genética , Venenos de Escorpión/aislamiento & purificación , Venenos de Escorpión/uso terapéutico , Resultado del Tratamiento , Canales de Sodio Activados por Voltaje/efectos de los fármacos
9.
Mol Cancer ; 13: 48, 2014 Mar 06.
Artículo en Inglés | MEDLINE | ID: mdl-24602443

RESUMEN

BACKGROUND: Nuclear factor-erythroid 2-related factor 2 (Nrf2) has emerged as a novel target for the prevention of colorectal cancer (CRC). Many chemopreventive compounds associated with Nrf2 activation are effective in preclinical systems and many on-going clinical trials are showing promising findings. In present study we evaluated the cytoprotective effect and chemopreventive properties of dietary digitoflavone. METHOD: A cell based Antioxidant Response Element (ARE)-driven luciferase reporter system was applied to screen potential Nrf2 activators. Activation of Nrf2 by digitoflavone was confirmed through mRNA, protein and GSH level assay in Caco-2 cell line. The cytoprotective effect of digitoflavone was evaluated in H2O2-induced oxidative stress model and further signaling pathways analysis was used to determine the target of digitoflavone induced Nrf2 activation. An AOM-DSS induced colorectal cancer model was used to assess the chemopreventive effect of digitoflavone. RESULT: Micromolarity (10 µM) level of digitoflavone increased Nrf2 expressing, nuclear translocation and expression of downstream phase II antioxidant enzymes. Furthermore, digitoflavone decreased H2O2-induced oxidative stress and cell death via p38 MAPK-Nrf2/ARE pathway. In vivo study, 50 mg/kg digitoflavone significantly reduced AOM-DSS induced tumor incidence, number and size. CONCLUSION: These observations suggest that digitoflavone is a novel Nrf2 pathway activator, and protects against oxidative stress-induced cell injury. The results of the present study add further evidence of the molecular mechanisms that allow digitoflavone to exert protective effects and reaffirm its potential role as a chemopreventive agent in colorectal carcinogenesis.


Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Carcinogénesis/efectos de los fármacos , Neoplasias del Colon/metabolismo , Flavonas/farmacología , Factor 2 Relacionado con NF-E2/metabolismo , Transducción de Señal/efectos de los fármacos , Animales , Western Blotting , Células CACO-2 , Quimioprevención , Colitis/patología , Neoplasias del Colon/prevención & control , Dieta , Técnica del Anticuerpo Fluorescente , Células HEK293 , Células HT29 , Células Hep G2 , Humanos , Inflamación/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Especies Reactivas de Oxígeno/metabolismo , Reacción en Cadena en Tiempo Real de la Polimerasa
10.
J Ethnopharmacol ; 337(Pt 1): 118794, 2024 Sep 05.
Artículo en Inglés | MEDLINE | ID: mdl-39244178

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Processed Buthus martensii Karsch (BmK) scorpion, also known as Quan-Xie, is a traditional Chinese medicine that is clinically used for the treatment of NAFLD due to its Tong-Luo-San-Jie effects. Our previous study showed that aqueous extract of processed BmK scorpion venom gland (pVg AE) inhibited macrophage inflammation by targeting Kv1.3 and identified the thermostable peptide BmKK2 as a potent Kv1.3 blocker. AIM OF THE STUDY: This study examined the therapeutic effects of processed BmK scorpions on NASH, specifically focusing on the involvement of their anti-inflammatory effects mediated by macrophage-expressed Kv1.3 in NASH. MATERIALS AND METHODS: In the present study, the anti-NASH effects of pVg AE were evaluated in high-fat diet (HFD)-induced NASH mouse models. Additionally, the in vitro anti-inflammatory mechanisms of pVg AE and BmKK2 were assessed using a palmitic acid (PA)-induced mouse bone marrow-derived macrophages (BMDMs) inflammation model. Protein and cytokine expression related to the Kv1.3-NF-κB pathway was analyzed by real-time PCR, immunoblotting and ELISA. The effect of pVg AE and BmKK2 on potassium channels was detected by whole-cell voltage-clamp recordings on transfected HEK293T cells or mouse BMDMs. Calcium ion imaging was used to evaluate intracellular calcium signaling. Furthermore, the study utilized Kv1.3 siRNA and a BMDMs and hepatocytes co-culture model to investigate the specific role of Kv1.3 in mediating the anti-NASH effects of pVg AE and BmKK2. RESULTS: Lipid accumulation upregulated Kv1.3 expression in macrophages in vivo and in vitro. However, pVg AE significantly reduced Kv1.3 expression and Kv1.3-positive macrophage infiltration. Treatment with pVg AE improved obesity, insulin resistance (IR), hepatic steatosis (HS), inflammation, and fibrosis in HFD-fed mice. Mechanistically, pVg AE and BmKK2 inhibited macrophage inflammation by targeting Kv1.3, which reduced PA-induced intracellular Ca2+ levels, resulting in the inhibition of the NF-κB pathway and TNFα release. CONCLUSIONS: This study demonstrates that Kv1.3-mediated macrophage inflammation is involved in the pathogenesis and treatment of NASH. pVg AE effectively alleviates metabolic stress-induced NASH by inhibiting this inflammation.

11.
Phytomedicine ; 128: 155500, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38484627

RESUMEN

Ginger, a well-known spice plant, has been used widely in medicinal preparations for pain relief. However, little is known about its analgesic components and the underlying mechanism. Here, we ascertained, the efficacy of ginger ingredient 8-Shogaol (8S), on inflammatory pain and tolerance induced by morphine, and probed the role of TRPV1 in its analgesic action using genetic and electrophysiology approaches. Results showed that 8S effectively reduced nociceptive behaviors of mice elicited by chemical stimuli, noxious heat as well as inflammation, and antagonized morphine analgesic tolerance independent on opioid receptor function. Genetic deletion of TRPV1 significantly abolished 8S' analgesia action. Further calcium imaging and patch-clamp recording showed that 8S could specifically activate TRPV1 in TRPV1-expressing HEK293T cells and dorsal root ganglion (DRG) neurons. The increase of [Ca2+]i in DRG was primarily mediated through TRPV1. Mutational and computation studies revealed the key binding sites for the interactions between 8S and TRPV1 included Leu515, Leu670, Ile573, Phe587, Tyr511, and Phe591. Further studies showed that TRPV1 activation evoked by 8S resulted in channel desensitization both in vitro and in vivo, as may be attributed to TRPV1 degradation or TRPV1 withdrawal from the cell surface. Collectively, this work provides the first evidence for the attractive analgesia of 8S in inflammatory pain and morphine analgesic tolerance mediated by targeting pain-sensing TRPV1 channel. 8S from dietary ginger has potential as a candidate drug for the treatment of inflammatory pain.


Asunto(s)
Catecoles , Ganglios Espinales , Canales Catiónicos TRPV , Zingiber officinale , Canales Catiónicos TRPV/metabolismo , Zingiber officinale/química , Animales , Humanos , Células HEK293 , Ganglios Espinales/efectos de los fármacos , Ganglios Espinales/metabolismo , Catecoles/farmacología , Ratones , Masculino , Ratones Endogámicos C57BL , Inflamación/tratamiento farmacológico , Analgésicos/farmacología , Morfina/farmacología , Calcio/metabolismo
12.
Bioorg Med Chem ; 21(1): 84-92, 2013 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-23218780

RESUMEN

A series of new scopoletin derivatives were designed and synthesized. Their anti-proliferative effect was initially evaluated against various human cancer cell lines. Among the tested compounds, A1, A2, and D6 showed significant anti-proliferative activities. Angiogenesis was detected by endothelial cell migration assay and tube formation study. The results showed that A1, A2, and D6 inhibited the vascular endothelial growth factor (VEGF)-stimulated proliferation, migration, and tube formation of human umbilical vein endothelial cells in vitro. Moreover, they inhibited the vessel growth in the chorioallantoic membrane in vivo. This inhibition was correlated with a significant decrease in the VEGF-triggered phosphorylated forms of ERK1/2 and Akt. In summary, these findings strongly suggested that these scopoletin derivatives might be structurally novel angiogenesis inhibitors.


Asunto(s)
Inhibidores de la Angiogénesis/química , Inhibidores de la Angiogénesis/farmacología , Antineoplásicos/química , Antineoplásicos/farmacología , Escopoletina/química , Escopoletina/farmacología , Línea Celular Tumoral , Movimiento Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Células Endoteliales de la Vena Umbilical Humana , Humanos , Neoplasias/tratamiento farmacológico , Factor A de Crecimiento Endotelial Vascular/metabolismo
13.
Appl Microbiol Biotechnol ; 97(19): 8547-58, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23324801

RESUMEN

Antagonists of tumor necrosis factor alpha (TNFa) have revolutionized the treatment of selected inflammatory diseases. Recombination Camelidae variable heavy-chain domain-only TNFa antibodies (anti-TNF-VHH) have been developed to antagonize the action of human and murine TNFa. Here, we describe a strategy to obtain functional covalent dimer anti-TNF-VHH molecules with the C-terminal fusion of human IgG1 Fc domain named anti-TNF-VHH-Fc. The resulting fusion proteins were separately expressed by use of the pET28a vector in Escherichia coli ((Ec)) strain BL21 and the pPICZaA vector in Pichia pastoris ((Pp)) strain GS115, then purified by protein A affinity resin. Fc-engineered anti-(Ec)TNF-VHH-Fc was about 40 kDa and anti-(Pp)TNF-VHH-Fc was about 43 kDa. Monomeric VHH was also cloned and expressed in E. coli strain BL21, with the molecular weight of about 18 kDa. Enzyme-linked immunosorbent assay and L929 cell cytotoxicity assay demonstrated that the fusion protein anti-(Pp)TNF-VHH-Fc blocked TNFa activity more effectively than either anti-(Ec)TNF-VHH-Fc or monomeric anti-(Ec)TNF-VHH protein. We suggest that efficient disulfide bond formation using the P. pastoris expression system improves the covalent dimer anti-TNF-VHH-Fc neutralizing activity.


Asunto(s)
Anticuerpos Neutralizantes/inmunología , Anticuerpos de Dominio Único/inmunología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Animales , Anticuerpos Neutralizantes/química , Anticuerpos Neutralizantes/genética , Anticuerpos Neutralizantes/aislamiento & purificación , Camelus , Humanos , Ratones , Peso Molecular , Pichia/genética , Pichia/metabolismo , Multimerización de Proteína , Proteínas Recombinantes de Fusión/química , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/inmunología , Proteínas Recombinantes de Fusión/aislamiento & purificación , Anticuerpos de Dominio Único/química , Anticuerpos de Dominio Único/genética , Anticuerpos de Dominio Único/aislamiento & purificación
14.
J Tradit Chin Med ; 33(1): 98-102, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23596820

RESUMEN

OBJECTIVE: To investigated the role of Mailuoning in the prevention of high-glucose-mediated cell apoptosis in human umbilical vein endothelial cells (HUVEC) and the mechanisms involved. METHODS: MTT assay was used to investigate cell viability, western blot was used to investigate protein expression, and flow cytometric detection technology was used to detect cell apoptosis. RESULTS: Exposure of HUVEC to high glucose (50 mM) significantly suppressed cell viability and increased cell apoptosis compared with normal glucose (11 mM) (all P < 0.05). However, Mailuoning prevented high-glucose-induced HUVEC apoptosis in dose-dependent manner. Further studies indicated that Mailuoning suppressed high-glucose-induced p38 mitogen-activated protein kinase phosphorylation, but had no effect on extracellular signal-regulated kinase 1/2 and Akt phosphorylation. CONCLUSION: Mailuoning can prevent high-glucose-induced HUVEC apoptosis by suppressing p38 activation.


Asunto(s)
Apoptosis/efectos de los fármacos , Medicamentos Herbarios Chinos/farmacología , Glucosa/toxicidad , Células Endoteliales de la Vena Umbilical Humana/citología , Supervivencia Celular/efectos de los fármacos , Células Endoteliales de la Vena Umbilical Humana/efectos de los fármacos , Células Endoteliales de la Vena Umbilical Humana/metabolismo , Humanos , Transducción de Señal/efectos de los fármacos , Proteínas Quinasas p38 Activadas por Mitógenos/genética , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
15.
Neuroreport ; 34(4): 220-231, 2023 03 01.
Artículo en Inglés | MEDLINE | ID: mdl-36719835

RESUMEN

OBJECTIVES: This study was aimed at evaluating the effects of dexpramipexole (DPX) - a mitochondrial protectant that sustains mitochondrial function and energy production - on cognitive function in a mouse model of sepsis-associated encephalopathy (SAE) induced by peripheral administration of lipopolysaccharide (LPS) and examining the potential mechanisms. METHODS: C57BL/6 male mice were randomized into one of four treatment protocols: Con+Sal, Con+DPX, LPS+Sal or LPS+DPX. The mice were intraperitoneally (i.p.) injected with LPS or equivalent volumes of normal saline once daily for 3 consecutive days. To evaluate the protective effects of DPX, we administered DPX or normal saline i.p. to the mice once daily for 6 consecutive days. Six mice in each group were decapitated on day 7, and each brain was rapidly removed and separated into two halves for biochemical and histochemical analysis. The remaining surviving mice in each group were subjected to behavioral tests from days 7 to 10. RESULTS: Peripheral administration of LPS to mice led to learning and memory deficits in behavioral tests, which were associated with mitochondrial impairment and ATP depletion in the hippocampus. Repeated DPX treatment protected the mitochondria against LPS-induced morphological and functional impairment; inhibited the activation of the Nod-like receptor pyrin domain-containing 3 (NLRP3) inflammasome-caspase-1-dependent pyroptosis pathway and cytochrome c (Cyt-c)-caspase-3-dependent apoptosis pathway; and attenuated LPS-induced neuroinflammation and cell death in the hippocampus in SAE mice. CONCLUSIONS: Mitochondria-mediated pyroptosis and apoptosis are involved in the pathogenesis of cognitive deficits in a mouse model of SAE and DPX protects mitochondria and suppresses the mitochondria-medicated pyroptosis and apoptosis pathways, and ameliorates LPS-induced neuroinflammation and cognitive deficits. This study provides theoretical evidence supporting DPX for the treatment of SAE.


Asunto(s)
Encefalopatía Asociada a la Sepsis , Masculino , Ratones , Animales , Encefalopatía Asociada a la Sepsis/tratamiento farmacológico , Piroptosis , Pramipexol , Lipopolisacáridos/toxicidad , Enfermedades Neuroinflamatorias , Solución Salina/metabolismo , Solución Salina/farmacología , Ratones Endogámicos C57BL , Apoptosis , Cognición , Mitocondrias/metabolismo
16.
J Ethnopharmacol ; 314: 116624, 2023 Oct 05.
Artículo en Inglés | MEDLINE | ID: mdl-37182676

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Inflammation plays pivotal role in the development of chronic diseases. Reducing chronic inflammation is an important strategy for preventing and managing many chronic diseases. In traditional Chinese medicine, the processed Buthus martensii Karsch (BmK) scorpion (also called "Quanxie") has been used to treat chronic inflammatory arthritis and spondylitis for hundreds of years suggests that "Quanxie" could potentially be utilized as a resource for identifying new anti-inflammatory compounds. However, the molecular basis and the underline mechanism for the anti-inflammatory effect of processed BmK scorpion are still unclear. AIM OF THE STUDY: The study aims to determine the potential involvement of macrophage-expressed Kv1.3 in the anti-inflammatory effect of processed BmK scorpion venom, as well as to identify new Kv1.3 blockers derived from processed BmK scorpion. MATERIALS AND METHODS: In this study, the in vivo and in vitro anti-inflammatory activities were determined using carrageenan-induced paw edema, LPS-induced sepsis mouse models and LPS-induced macrophage activation model respectively. The effect of processed BmK scorpion water extract, processed BmK venom and BmKK2 on different potassium channels were detected by whole-cell voltage-clamp recordings on transfected HEK293 cells or mouse BMDMs. The cytokines were detected using Q-PCR and competitive enzyme-linked immunosorbent assay. High performance liquid chromatography, SDS-PAGE and peptide Mass Spectrometry analysis were used to isolate and identify the BmKK2. SiRNA, western blotting and flow cytometry were used to analysis the anti-inflammatory mechanism of BmKK2. RESULTS: Here we demonstrate that BmKK2, a thermostable toxin targeting Kv1.3 is the critical anti-inflammatory component in the processed BmK scorpion. BmKK2 inhibits inflammation by targeting and inhibiting the activity of macrophage Kv1.3, thereby inhibiting the activation of NF-κB-NLRP3 pathway and the subsequent release of inflammatory factors. CONCLUSIONS: These findings provide new insights into the molecular basis of the anti-inflammatory effects of "Quanxie" and highlight the importance of targeting Kv1.3 expressed on macrophages as an anti-inflammatory approach.


Asunto(s)
FN-kappa B , Venenos de Escorpión , Ratones , Humanos , Animales , Escorpiones/química , Escorpiones/metabolismo , Proteína con Dominio Pirina 3 de la Familia NLR , Lipopolisacáridos , Células HEK293 , Macrófagos/metabolismo , Inflamación , Venenos de Escorpión/farmacología , Venenos de Escorpión/química
17.
Yao Xue Xue Bao ; 47(10): 1341-6, 2012 Oct.
Artículo en Zh | MEDLINE | ID: mdl-23289147

RESUMEN

Nanobody is a kind of antibody from camel, which misses light chain. Nanobody has the same antigen binding specificity and affinity as mAb. Moreover, because of its small molecular weight, high stability and easy preparation, nanobody has great value of biomedical applications. In this study, we successfully prepared highly pure antiEGFR nanobody in E.coli using genetic engineering techniques. Cell proliferation assay (CCK-8 assay) and migration experiments (cell scratch test and Transwell assay) indicated that the recombinant antiEGFRnano can significantly inhibit the proliferation and migration of endometrial cancer cells. These results provide a new way of thinking and methods for EGFR-targeted therapy of endometrial cancer.


Asunto(s)
Adenocarcinoma/patología , Movimiento Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Neoplasias Endometriales/patología , Receptores ErbB/inmunología , Anticuerpos de Dominio Único/farmacología , Adenocarcinoma/metabolismo , Secuencia de Aminoácidos , Secuencia de Bases , Línea Celular Tumoral , Neoplasias Endometriales/metabolismo , Receptores ErbB/genética , Escherichia coli/metabolismo , Estrógenos/metabolismo , Femenino , Vectores Genéticos , Humanos , Plásmidos , Proteínas Recombinantes/metabolismo , Anticuerpos de Dominio Único/genética
18.
Zhongguo Zhong Yao Za Zhi ; 37(9): 1259-64, 2012 May.
Artículo en Zh | MEDLINE | ID: mdl-22803372

RESUMEN

OBJECTIVE: To study luteolin-induced non-small cell lung cancer cell line A549 apoptosis and the molecular mechanism for inhibiting its cycle arrest (G2 stage). METHOD: MTT assay showed that luteolin had obvious inhibitory effect on A549 and indicated the half inhibition ratio (IC50). Cell cycle and apoptosis were detected by Hoechst 33258 nuclear staining assay, Annexin V-FITC/PI double staining and flow cytometry. Western blotting assay revealed changes in cycle and apoptosis-related proteins induced by luteolin. Possible molecular mechanism was suggested by Western blotting and immunocytochemistry. RESULT: Luteolin had an obvious growth inhibitory effect on A549 cells, with IC50 of 45.2 micromol x L(-1) at 48 h. Flow cytometry showed A549 cells mainly arrested in G2 stage after being treated by luteolin, with low expressions in cyclin A, p-CDC2 and p-Rb. Hoechst 33258 nuclear staining and Annexin V-FITC/PI double staining showed that the luteolin treatment group showed a significant apoptosis rate than the non-treatment group. Western blotting found luteolin can increase phosphorylation of JNK and decrease that of NF-kappaKB (p65). Immunocytochemistry results revealed luteolin can inhibit TNF-alpha-stimulated p65 from nuclear translocation as a transcription factor and thus promoting cell apoptosis. CONCLUSION: Luteolin can obviously induce apoptosis of human non-small cell lung cancer cell A549 possibly by increasing phosphorylation of JNK to activate mitochondria apoptosis pathway, while inhibiting NF-kappaB from nuclear translocation as a transcription factor.


Asunto(s)
Apoptosis/efectos de los fármacos , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Luteolina/farmacología , Anexina A5/metabolismo , Western Blotting , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Humanos , FN-kappa B/metabolismo
19.
J Ethnopharmacol ; 288: 114998, 2022 Apr 24.
Artículo en Inglés | MEDLINE | ID: mdl-35063590

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Chronic pain management represents a serious healthcare problem worldwide. The use of opioid analgesics for pain has always been hampered by their side effects; in particular, the addictive liability associated with chronic use. Finding a morphine replacement has been a long-standing goal in the field of analgesia. In traditional Chinese medicine, processed Buthus martensii Karsch (BmK) scorpion has been used as a painkiller to treat chronic inflammatory arthritis and spondylitis, so called "Scorpio-analgesia". However, the molecular basis and the underline mechanism for the Scorpio-analgesia are still unclear. AIM OF THE STUDY: The study aims to investigate the molecular basis of "Scorpio analgesia" and identify novel analgesics from BmK scorpion. MATERIALS AND METHODS: In this study, the analgesic abilities were determined using formalin-, acetic acid- and complete Freund's adjuvant-induced pain models. The effect of BmK venom and processed BmK venom on Nav1.7 were detected by whole-cell voltage-clamp recordings on HEK293-hNav1.7 stable cell line. Action potentials in Dorsal root ganglion (DRG) neurons induced by Makatoxin-3-R58A were recorded in current-clamp mode. The content of Makatoxin-3 was detected using competitive enzyme-linked immunosorbent assay based on the Makatoxin-3 antibody. High performance liquid chromatography, western blot and circular dichroism spectroscopy were used to analysis the stability of Makatoxin-3. RESULTS: Here we demonstrate that Makatoxin-3, an α-like toxin in BmK scorpion venom targeting Nav1.7 is the critical component in Scorpio-analgesia. The analgesic effect of Makatoxin-3 could not be reversed by naloxone and is more potent than Nav1.7-selective inhibitors and non-steroidal anti-inflammatory drugs in inflammatory models. Moreover, a R58A mutant of Makatoxin-3 is capable of eliciting analgesia effect without inducing pain response. CONCLUSIONS: This study advances ion channel biology and proposes Nav1.7 agonists, rather than the presumed Nav1.7-only blockers, for non-narcotic relief of chronic pain.


Asunto(s)
Analgésicos/farmacología , Inflamación/tratamiento farmacológico , Dolor/tratamiento farmacológico , Venenos de Escorpión/farmacología , Potenciales de Acción/efectos de los fármacos , Analgésicos/aislamiento & purificación , Animales , Modelos Animales de Enfermedad , Adyuvante de Freund , Ganglios Espinales/efectos de los fármacos , Células HEK293 , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Canal de Sodio Activado por Voltaje NAV1.7/efectos de los fármacos , Neuronas/efectos de los fármacos , Dolor/patología , Agonistas del Canal de Sodio Activado por Voltaje/aislamiento & purificación , Agonistas del Canal de Sodio Activado por Voltaje/farmacología
20.
Pain ; 163(2): e202-e214, 2022 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-34252912

RESUMEN

ABSTRACT: Gain-of-function and loss-of-function mutations in Nav1.7 cause chronic pain and pain insensitivity, respectively. The preferential expression of Nav1.7 in the peripheral nervous system and its role in human pain signaling make Nav1.7 a promising target for next-generation pain therapeutics. However, pharmacological agents have not fully recapitulated these pain phenotypes, and because of the lack of subtype-selective molecular modulators, the role of Nav1.7 in the perception of pain remains poorly understood. Scorpion venom is an excellent source of bioactive peptides that modulate various ion channels, including voltage-gated sodium (Nav) channels. Here, we demonstrate that Buthus martensii Karsch scorpion venom (BV) elicits pain responses in mice through direct enhancement of Nav1.7 activity and have identified Makatoxin-3, an α-like toxin, as a critical component for BV-mediated effects on Nav1.7. Blocking other Nav subtypes did not eliminate BV-evoked pain responses, supporting the pivotal role of Nav1.7 in BV-induced pain. Makatoxin-3 acts on the S3-S4 loop of voltage sensor domain IV (VSD4) of Nav1.7, which causes a hyperpolarizing shift in the steady-state fast inactivation and impairs inactivation kinetics. We also determined the key residues and structure-function relationships for the toxin-channel interactions, which are distinct from those of other well-studied α toxins. This study not only reveals a new mechanism underlying BV-evoked pain but also enriches our knowledge of key structural elements of scorpion toxins that are pivotal for toxin-Nav1.7 interactions, which facilitates the design of novel Nav1.7 selective modulators.


Asunto(s)
Dolor Crónico , Picaduras de Escorpión , Venenos de Escorpión , Animales , Dolor Crónico/genética , Humanos , Ratones , Fenotipo , Venenos de Escorpión/química , Venenos de Escorpión/toxicidad , Escorpiones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA